Phase Ib/II study of Cetuximab Plus Pembrolizumab in Patients with Advanced RAS wild-type Colorectal Cancer

CONCLUSIONS: The combination of cetuximab and pembrolizumab is inactive in patients with RASwt mCRC, despite its partial local immunologic efficacy. Further development of immuno-oncology combinations with enhanced efficacy and/or targeting additional or alternative immune checkpoints merits investigation.PMID:34645646 | DOI:10.1158/1078-0432.CCR-21-1650

Source: Clinical Cancer Research - October 14, 2021 Category: Cancer & Oncology Authors: Christos Fountzilas David L Bajor Sarbajit Mukherjee Joel Saltzman Agnieszka K Witkiewicz Orla Maguire Hans Minderman Ram Nambiar Hanna R Rosenheck Erik S Knudsen Jason B Muhitch Scott I Abrams Chong Wang Alan D Hutson Kristopher Attwood Karen A Hicks Jen Source Type: research